University of Missouri-Kansas City

SAN FRANCISCO, March 19, 2025 /PRNewswire/ -- Today Glaucoma Research Foundation (GRF) announced the nine recipients of its $55,000 one-year Shaffer Research Grants. "We are extremely fortunate for the ongoing and generous investment from our glaucoma community which enables these promising areas of research to be explored," said Thomas M. Brunner, GRF President and CEO. "These one-year incubator grants attract much-needed brainpower to the field of glaucoma and move us ever closer to the discovery of new treatments to preserve and restore vision." GRF is grateful to the generous donors who funded the 2025 Shaffer Research Grants. The Arlene Anthony Grant for Innovative Glaucoma Research Joel Palko, MD West Virginia University School of Medicine Project: Impact of Low Blood Pressure on ONH Biomechanics in Glaucoma The Larry Haimovitch Grant for Innovation in Ophthalmology Shruthi Karnam, PhD University of California, Berkeley Project: Targeting Lipoxin B4 for Reversing Astrocyte-Mediated Neuroinflammation in Glaucoma The Mary Dell Hibbert Glaucoma Research Fund Richard Eva, PhD King's College London Project: Pro-Tect and Restore: Developing Pro-trudinPlus Gene Therapy The Rajen Savjani Fund for Innovative Glaucoma Research Vidhya Rao, PhD Loyola University Chicago Project: Role of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase-4 (NOX4) induced mitochondrial dysfunction in Primary Open Angle Glaucoma The Rajen Savjani Fund for Innovative Glaucoma Research Supraja Varadarajan, PhD University of Texas Southwestern Medical Center Project: The Role of Postsynaptic Targets in Preserving Vision The Linda and Gary Sirak Glaucoma Research Fund Karl Kador, PhD University of Missouri–Kansas City Project: Reintroducing Developmentally Regulated Guidance Factors to the Optic Nerve The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research Steven Barnes, PhD Doheny Eye Institute, UCLA Project: Intrinsic Ion Channels Reduce Excitability During Energy Stress The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research Fiona McDonnell, PhD Moran Eye Center, University of Utah Project: Extracellular Vesicle Regulation of ECM in the Lamina Cribrosa The Zander Family Research Fund for Glaucoma Genetics Balasankara Reddy Kaipa, PhD University of California, Irvine Project: The Genetics of Glaucoma: Lipid nanoparticle-mediated delivery of base editor ribonucleoprotein complex targeting the trabecular meshwork for the treatment of glaucoma To date, GRF has awarded more than 300 Shaffer Research Grants. To learn more, visit . About Glaucoma Research Foundation SOURCE Glaucoma Research Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WASHINGTON, Dec. 12, 2024 /PRNewswire/ -- Today, the American Pharmacists Association (APhA) began announcing the selection of the 2025 APhA Awards and Honors Program recipients. The APhA Awards and Honors Program is the most comprehensive recognition program in the profession of pharmacy. All honorees in the profession-wide, practitioner, research, and student pharmacist categories will be announced over the next few weeks and can be found on APhA's  awards website. Recipients will be officially recognized during the  APhA Annual Meeting & Exposition in Nashville, TN, March 21–24, 2025. The Remington Honor Medal was named for eminent community pharmacist, manufacturer, and educator, Joseph P. Remington and was established in 1918 to recognize distinguished service on behalf of American pharmacy during the preceding years that culminate in the past year or during a long period of outstanding activity or fruitful achievement. It serves as the preeminent award for the profession of pharmacy and is the highest honor bestowed by APhA. Stephen W. Schondelmeyer, PharmD, PhD, of Minneapolis, MN, was selected as the recipient of the 2025 Remington Honor Medal. Schondelmeyer's impact and expertise from over 50 years of research includes improving prescription drug access and affordability, encouraging drug price competition, shaping drug benefit plan management and prescription drug reimbursement, documenting pharmacists' compensation and workforce trends, and establishing policy to reduce drug shortages and improve drug supply resilience. His work experience has encompassed activities in practice, academia, professional associations, and state and federal government. Dr. Schondelmeyer is currently a professor of Pharmaceutical Economics in the College of Pharmacy at the University of Minnesota where he holds the Century Mortar Club Endowed Chair in Pharmaceutical Management & Economics. Dr. Schondelmeyer established and is Director of the PRIME Institute at the University of Minnesota, which conducts economic and public policy research on the roles of pharmacists and pharmaceuticals in society. Schondelmeyer's nominators note that "his work has shaped medication and health policy as we know it today." One nominator highlighted Schondelmeyer's broad efforts to share "who pharmacists are" and "how they can improve the distribution and use of medications in society" to those outside of the pharmacy profession, which has greatly increased public visibility on the value of pharmacists. Another nominator noted his contribution to the body of knowledge and efforts to share this knowledge broadly are unmatched with 930 invited presentations, 260 scientific peer reviewed papers, posters, and presentations, 174 technical reports, books, and book chapters about drug pricing, supply chain management, drug shortages, and pharmacy policy, and 160 presentations and testimony to Congress, state legislatures, and other governmental entities. In addition to his own research endeavors, Schondelmeyer has served as an expert on numerous state and national task forces and boards where he shares the value of pharmacy and improves patient lives through policy. Schondelmeyer has received numerous awards and honors, including APhA's Hubert H. Humphrey Award and the Tyler Prize for the Stimulation of Research. He has also received the Hall of Distinguished Alumni Lifetime Achievement Award from the University of Kentucky College of Pharmacy, the Weaver Medal from the University of Minnesota College of Pharmacy, and the Leadership in Action Award from the Minnesota Health Action Group. Schondelmeyer earned his BSPharm from the University of Missouri-Kansas City (1974), an ASHP Residency and Doctor of Pharmacy from the University of Kentucky (1977), and master's in public administration (1979) and PhD in pharmacy administration (1984) from The Ohio State University. For every pharmacist, for all of pharmacy. SOURCE American Pharmacists Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, Nov. 5, 2024 -- For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement in symptoms, function, and quality of life, according to a study published online Oct. 30 in the Journal of the American College of Cardiology . The research was published to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C. Suzanne V. Arnold, M.D., from the Saint Luke's Mid America Heart Institute/University of Missouri-Kansas City, and colleagues performed an in-depth analysis of the health status of patients enrolled in the TRISCEND II pivotal trial. Patients with symptomatic and severe or greater TR were randomly assigned to TTVR with the EVOQUE tricuspid valve replacement system plus OMT or OMT alone (259 and 133 patients, respectively). The researchers found that at each follow-up time point, significantly greater improvement in both disease-specific and general health status was seen for patients receiving TTVR + OMT. At each time point, the mean between-group differences in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score favored TTVR + OMT: 11.8, 20.8, and 17.8 points at 30 days, six months, and one year, respectively. Health status was improved by TTVR + OMT to a greater extent among patients with torrential or massive TR versus severe TR. At one year, 64.6 and 31.0 percent of those receiving TTVR + OMT and OMT alone, respectively, were alive and well. "Further study is warranted to understand the long-term durability of these benefits as well as to identify the optimal patient population for this novel therapy," the authors write. The study was funded by Edwards Lifesciences, the manufacturer of the EVOQUE tricuspid valve replacement system. Abstract/Full Text More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.